EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Add-on PD-1 inhibitor with Peg-IFNα therapy favors functional cure of chronic hepatitis B patients

Yaping Li, Chenrui Liu, Liu Yang, Ling He, Mei Li, Guoe Gou, Dandan Feng, Xin Zhang, Fusheng Wang, Junliang Fu iD, Shuangsuo Dang iD

Journal of Translational Internal Medicine · 18.02.2026 · 14 (1) · 123-133

DOI: 10.1515/jtim-2026-0018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Translational Internal Medicine, online erschienen am 13.02.2026. Verfasst von Yaping Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province, China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives The treatment options for hepatitis B surface antigen (HBsAg) clearance are limited for patients who have failed pegylated interferon-α (Peg-IFNα) therapy. Given preclinical evidence that PD-1 blockade boosts antiviral immunity, this study aims to evaluate the efficacy and safety of PD-1 inhibitors in chronic hepatitis B (CHB) patients who have failed interferon therapy.

Methods

This non-randomized controlled trial was conducted in CHB patients who failed to achieve HBsAg clearance after 48 weeks of Peg-IFNα therapy. Including two groups: (i) a PD-1 inhibitor plus Peg-IFNα group receiving sintilimab 1 mg/kg/12 weeks plus Peg-IFNα 180 μg/week ( n = 33) or (ii) a Peg-IFNα group continuing Peg-IFNα therapy ( n = 31). The primary endpoint was HBsAg clearance at week 24.

Results

The PD-1 inhibitor plus Peg-IFNα group included 33 patients and the Peg-IFNα group included 31 patients. At week 24, HBsAg clearance occurred in 30.3% of PD-1 inhibitor plus Peg-IFNα group versus 9.7% of Peg-IFNα group ( P = 0.047). Median HBsAg declined by –0.916 log 10 IU/mL in the PD-1 inhibitor plus Peg-IFNα group compared with –0.067 log 10 IU/mL in Peg-IFNα group ( P = 0.013). In the PD-1 inhibitor plus Peg-IFNα group, alanine transaminase (ALT) rose transiently at week 12 only among patients who ultimately cleared HBsAg. Sintilimab increased stomatitis (12.1%) and recurrent fever (36.4%), but the frequency of grade ≥ 3 adverse events did not differ from Peg-IFNα group. Enzyme-linked immunosorbent assay (ELISA) profiling showed progressive induction of ISG15 after sintilimab, and patients achieving HBsAg clearance displayed higher baseline and week-12 OAS1 concentrations than non-clearers (both P < 0.05).

Conclusions

Quarterly sintilimab add-on therapy triples the short-term HBsAg clearance rate in interferon-refractory CHB without major additional toxicity. A week-12 ALT surge and elevated OAS1 may serve as early biomarkers of response, but confirmation in larger randomized trials is needed.

Schlagwörter

Stichwörter der Autor:innen

HBsAg clearancePD-1 inhibitorchronic hepatitis Bfunctional curehepatitis B viruspegylated interferon-αsintilimab

Autor:innen und Institutionen

  • Department of Infectious Diseases, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province, China.
  • Senior Department of Infectious Diseases, Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.

ORCID-Profile: Junliang Fu, Shuangsuo Dang

Zitieren

APA

Li, Y., Liu, C., Yang, L., He, L., Li, M., Gou, G., Feng, D., Zhang, X., Wang, F., Fu, J., & Dang, S. (2026). Add-on PD-1 inhibitor with Peg-IFNα therapy favors functional cure of chronic hepatitis B patients. Journal of Translational Internal Medicine, 14(1), 123-133. https://doi.org/10.1515/jtim-2026-0018

Vancouver

Li Y, Liu C, Yang L, He L, Li M, Gou G, et al. Add-on PD-1 inhibitor with Peg-IFNα therapy favors functional cure of chronic hepatitis B patients. Journal of Translational Internal Medicine. 2026;14(1):123-133. doi:10.1515/jtim-2026-0018

BibTeX
@article{Li2026,
  author = {Li, Yaping and Liu, Chenrui and Yang, Liu and He, Ling and Li, Mei and Gou, Guoe and Feng, Dandan and Zhang, Xin and Wang, Fusheng and Fu, Junliang and Dang, Shuangsuo},
  title = {Add-on PD-1 inhibitor with Peg-IFNα therapy favors functional cure of chronic hepatitis B patients},
  journal = {Journal of Translational Internal Medicine},
  year = {2026},
  volume = {14},
  number = {1},
  pages = {123--133},
  doi = {10.1515/jtim-2026-0018}
}
Kostenlos starten →